<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03023722</url>
  </required_header>
  <id_info>
    <org_study_id>1608018265</org_study_id>
    <nct_id>NCT03023722</nct_id>
  </id_info>
  <brief_title>Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer</brief_title>
  <official_title>An Open-label, Phase II Study of Intravenous Anetumab Ravtansine (BAY 94-9343), an Anti-mesothelin Antibody Drug Conjugate, in Pretreated Mesothelin-expressing Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to:&#xD;
&#xD;
      -Test the activity/response rate per RECIST 1.1 criteria of anetumab ravtansine in patients&#xD;
      with advanced pancreatic cancer who stain for mesothelin expression&#xD;
&#xD;
      The secondary objectives of this study are to:&#xD;
&#xD;
        -  Time to Progression (TTP) defined as time from study treatment to RECIST 1.1&#xD;
           progression, or death (others going off study will be censored)&#xD;
&#xD;
        -  Toxicity in pancreatic cancer patients (at 6.5 mg/kg dose)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-randomized, open-label, multicenter, Phase II study to evaluate the efficacy&#xD;
      and safety of intravenous anetumab ravtansine (BAY 94-9343), an anti-mesothelin antibody drug&#xD;
      conjugate, in pretreated mesothelin-expressing advanced pancreatic cancer.&#xD;
&#xD;
      At the time of the start of study treatment, the patients will have pretreated advanced&#xD;
      pancreatic cancer that also overexpresses mesothelin as determined by immunohistochemistry&#xD;
      (IHC).&#xD;
&#xD;
      A maximum of 30 patients will be enrolled in a minimax, Simon 2-stage design with a single&#xD;
      early stopping rule for lack of efficacy. The target population is those patients with&#xD;
      pancreatic cancer who have failed an earlier treatment. All patients will be treated with an&#xD;
      anti-mesothelin immuno-conjugate, in this single arm, non-randomized trial and all patients&#xD;
      treated with at least one dose of Anetumab will be included. The endpoint is any response&#xD;
      using the RECIST 1.1 criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 11, 2017</start_date>
  <completion_date type="Actual">December 11, 2019</completion_date>
  <primary_completion_date type="Actual">August 6, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate as Measured Per RECIST 1.1 Criteria</measure>
    <time_frame>From start of treatment until disease progression or death (up to 3 years).</time_frame>
    <description>Primary efficacy will be assessed based on radiological tumor evaluation by contrast-enhanced computed tomography (CT) or contrast-enhanced magnetic resonance imaging (MRI) of chest/abdomen/pelvis. Contrast enhanced RECIST 1.1 scan will be done at Prescreening. Said pre-screen scan will be the baseline measure. RECIST 1.1 Scans will be done every 6 weeks for the first 6 months after the start of treatment, or more frequently if clinically indicated, every 9 weeks until the end of year 2 and every 12 weeks thereafter until disease progression or end of study, whichever comes first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>From start of treatment until disease progression or death (up to 3 years).</time_frame>
    <description>Time to Progression (TTP) defined as time from study treatment to RECIST progression, or death (others going off study will be censored).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug Toxicity</measure>
    <time_frame>From start of treatment until disease progression or death (up to 3 years).</time_frame>
    <description>Toxicity of Anetumab ravtansine assessed with National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. See adverse events for details. Participants who experienced any adverse events are included here.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>All Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with advanced metastatic pancreatic cancer who have measurable disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anetumab ravtansine</intervention_name>
    <description>Patients will receive anetumab ravtansine IV infusion at a dose of 6.5 mg/kg (recommended Phase II dose) on Day 1 of a 21-day cycle</description>
    <arm_group_label>All Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Eligibility criteria for prescreening&#xD;
&#xD;
          -  Must have had at least one and not more than two prior chemotherapy regimens for&#xD;
             advanced disease (neoadjuvant or adjuvant chemotherapy would not be counted as a line&#xD;
             of therapy). If prior radiation, measurable lesion outside radiation portal.&#xD;
&#xD;
          -  Written informed consent for prescreening.&#xD;
&#xD;
          -  Unresectable locally advanced or metastatic pancreatic cancer, confirmed by histology&#xD;
&#xD;
          -  Availability of archival or fresh tissue for testing of mesothelin expression level.&#xD;
&#xD;
        Note: Archival tissue is preferred and fresh biopsy should only be obtained if no archival&#xD;
        tissue is available and if in the investigator's judgement, there is no additional risk for&#xD;
        the patient's safety. Patients with a sarcomatoid histology are not expected to have&#xD;
        mesothelin overexpression and should not enter prescreening.&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Life expectancy of at least 3 months.&#xD;
&#xD;
          -  No prior treatment with anetumab ravtansine (or any other mesothelin-based therapy)&#xD;
&#xD;
        Eligibility criteria for full study&#xD;
&#xD;
          -  Written informed consent for full study.&#xD;
&#xD;
          -  Histological documentation of overexpressing mesothelin at the moderate (2+) or&#xD;
             stronger (3+) level in at least 30% of tumor cells as determined by IHC.&#xD;
&#xD;
          -  Unresectable locally advanced or metastatic pancreatic cancer&#xD;
&#xD;
          -  At least one but not more than two prior chemotherapy regimens with progression or&#xD;
             documented intolerance (neoadjuvant or adjuvant chemotherapy would not be counted as a&#xD;
             line of therapy).&#xD;
&#xD;
          -  Patients must have at least 1 measurable lesion according to RECIST v 1.1&#xD;
&#xD;
          -  ECOG PS of 0 or 1&#xD;
&#xD;
          -  Life expectancy of at least 3 months.&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal function as assessed by the following laboratory&#xD;
             requirements conducted within 7 days before starting study treatment:&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 x the upper limit of normal (ULN). Documented Gilbert syndrome&#xD;
             is allowed if total bilirubin is mildly elevated (&lt; 6 mg/dL).&#xD;
&#xD;
          -  ALT and AST ≤ 2.5 x ULN (≤ 5 x ULN for patients with liver involvement of their&#xD;
             cancer).&#xD;
&#xD;
          -  ALP limit ≤ 2.5 x ULN (≤ 5 x ULN for patients with liver involvement of their cancer).&#xD;
&#xD;
          -  Extent of baseline tumor burden will not interfere with causal assessment of&#xD;
             treatment-emergent hepatotoxicity, at the investigator's discretion.&#xD;
&#xD;
          -  Amylase and lipase ≤ 1.5 x ULN.&#xD;
&#xD;
          -  Glomerular filtration rate (GFR) ≥ 30 mL/min/1.73 m2 according to the Modification of&#xD;
             Diet in Renal Disease (MDRD) abbreviated formula (see Appendix 16.6).&#xD;
&#xD;
          -  Adequate coagulation, as assessed by the following laboratory test results:&#xD;
&#xD;
          -  International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 x ULN (CTCAE Grade&#xD;
             ≤ 1).&#xD;
&#xD;
          -  Partial thromboplastin time (PTT) or activated PTT (aPTT) ≤ 1.5 x ULN (CTCAE Grade ≤&#xD;
             1).&#xD;
&#xD;
        Note: Patients on stable dose of anti-coagulation therapy will be allowed to participate if&#xD;
        they have no sign of bleeding or clotting and INR / PT and PTT / aPTT test results are&#xD;
        compatible with the acceptable benefit-risk ratio at the investigator's discretion&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm3 , without platelet transfusion within 3 weeks before the&#xD;
             start of study treatment.&#xD;
&#xD;
          -  Hemoglobin (Hb) ≥ 8 g/dL, without blood transfusion or erythropoietin within 6 weeks&#xD;
             before the start of study treatment.&#xD;
&#xD;
        Note: Patients on stable dose of anti-coagulation therapy will be allowed to participate if&#xD;
        they have no sign of bleeding or clotting and INR / PT and PTT / aPTT test results are&#xD;
        compatible with the acceptable benefit-risk ratio at the investigator's discretion (see&#xD;
        Section 8.1).&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥ 1000/mm3&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) ≥ 50% or the lower limit of normal (LLN)&#xD;
             according to local institution ranges of normality&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous assignment to treatment during this study. Patients permanently withdrawn&#xD;
             from study participation will not be allowed to re-enter the study.&#xD;
&#xD;
          -  Previous (within 5 drug half-lives - if drug half-life in subjects is known - or 28&#xD;
             days, whichever is shorter, before the start of study treatment) or concomitant&#xD;
             participation in another clinical study with investigational medicinal product(s)&#xD;
             (IMP[s]).&#xD;
&#xD;
          -  Patients with corneal epitheliopathy or any eye disorder that may predispose the&#xD;
             patients to this condition at the discretion of the investigator.&#xD;
&#xD;
          -  Previous or concurrent cancer that is distinct in primary site or histology within 5&#xD;
             years. Exceptions: curatively treated&#xD;
&#xD;
          -  Cervical cancer in situ.&#xD;
&#xD;
          -  Non-melanoma skin cancer.&#xD;
&#xD;
          -  Superficial bladder tumors (Non-invasive tumor [Ta], Carcinoma in situ [Tis] and Tumor&#xD;
             invades lamina propria [T1]).&#xD;
&#xD;
          -  Major surgery, open biopsy or significant traumatic injury within 28 days before the&#xD;
             start of study treatment.&#xD;
&#xD;
          -  Pregnant or breast-feeding patients. Women of childbearing potential must have a serum&#xD;
             pregnancy test performed a maximum of 7 days before the start of study treatment, and&#xD;
             a negative result must be documented before the start of study treatment.&#xD;
&#xD;
          -  Pre-existing cardiac conditions as outlined below:&#xD;
&#xD;
          -  Congestive heart failure ≥ New York Heart Association (NYHA) class 2.&#xD;
&#xD;
          -  Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3&#xD;
             months). Myocardial infarction less than 6 months before the start of study treatment.&#xD;
&#xD;
          -  Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are&#xD;
             permitted).&#xD;
&#xD;
          -  Clinically significant uncontrolled hypertension (systolic blood pressure &gt; 150 mmHg&#xD;
             or diastolic pressure &gt; 90 mmHg despite optimal medical management).&#xD;
&#xD;
          -  Arterial thrombotic or embolic events such as cerebrovascular accident (including&#xD;
             transient ischemic attacks), or venous pulmonary embolism within 6 months before the&#xD;
             start of study treatment; venous thrombotic events such as deep vein thrombosis within&#xD;
             3 months before the start of study treatment.&#xD;
&#xD;
          -  Ongoing or active infection (bacterial, fungal, or viral) of NCI-CTCAE version 4.03&#xD;
             Grade &gt; 2.&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          -  Known history of chronic hepatitis B or C.&#xD;
&#xD;
          -  Patients with seizure disorder requiring medication.&#xD;
&#xD;
          -  Symptomatic brain metastases or meningeal tumors or other uncontrolled metastases in&#xD;
             the central nervous system (CNS) unless the patient&#xD;
&#xD;
          -  Is &gt; 6 months from definitive therapy,&#xD;
&#xD;
          -  Has a negative imaging study within 4 weeks before study entry (ICF signature for full&#xD;
             study) and&#xD;
&#xD;
          -  Is clinically stable with respect to the tumor at the time of study entry.&#xD;
&#xD;
          -  History of organ allograft, stem cells or bone marrow transplant.&#xD;
&#xD;
          -  Patients with evidence or history of bleeding diathesis. Any hemorrhage or bleeding&#xD;
             event ≥ CTCAE Grade 3 within 4 weeks before the start of study treatment.&#xD;
&#xD;
          -  Non-healing wound, ulcer, or bone fracture.&#xD;
&#xD;
          -  Renal failure requiring peritoneal dialysis or hemodialysis.&#xD;
&#xD;
          -  Known hypersensitivity to anetumab ravtansine, study drug classes or excipients in the&#xD;
             formulation.&#xD;
&#xD;
          -  Any illness or medical conditions that are unstable or could jeopardize the safety of&#xD;
             the patient and his/her compliance in the study.&#xD;
&#xD;
          -  Unresolved toxicity higher than NCI-CTCAE version 4.03 Grade 1 attributed to any prior&#xD;
             therapy/procedure excluding anemia or neuropathy Grade 2 and alopecia of any Grade.&#xD;
&#xD;
          -  Any prohibited prior or concomitant therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stacey Stein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale Cancer Center, Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901-2163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 13, 2017</study_first_submitted>
  <study_first_submitted_qc>January 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2017</study_first_posted>
  <results_first_submitted>November 5, 2020</results_first_submitted>
  <results_first_submitted_qc>January 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 22, 2021</results_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maytansine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT03023722/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Subjects</title>
          <description>Patients with advanced metastatic pancreatic cancer who have measurable disease&#xD;
anetumab ravtansine: Patients will receive anetumab ravtansine IV infusion at a dose of 6.5 mg/kg (recommended Phase II dose) on Day 1 of a 21-day cycle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No follow-up assessment</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>Patients with advanced metastatic pancreatic cancer who have measurable disease&#xD;
anetumab ravtansine: Patients will receive anetumab ravtansine IV infusion at a dose of 6.5 mg/kg (recommended Phase II dose) on Day 1 of a 21-day cycle</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>50-59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-79 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80-89 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate as Measured Per RECIST 1.1 Criteria</title>
        <description>Primary efficacy will be assessed based on radiological tumor evaluation by contrast-enhanced computed tomography (CT) or contrast-enhanced magnetic resonance imaging (MRI) of chest/abdomen/pelvis. Contrast enhanced RECIST 1.1 scan will be done at Prescreening. Said pre-screen scan will be the baseline measure. RECIST 1.1 Scans will be done every 6 weeks for the first 6 months after the start of treatment, or more frequently if clinically indicated, every 9 weeks until the end of year 2 and every 12 weeks thereafter until disease progression or end of study, whichever comes first.</description>
        <time_frame>From start of treatment until disease progression or death (up to 3 years).</time_frame>
        <population>Of the 18 subjects originally enrolled, the analysis population includes the 14 subjects who completed the study. The original intention was to follow subjects for up to 3 years. However, all subjects died before the three year mark, so the study was concluded on Dec. 11.2019, after 2 years and 7 months.</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>Patients with advanced metastatic pancreatic cancer who have measurable disease&#xD;
anetumab ravtansine: Patients will receive anetumab ravtansine IV infusion at a dose of 6.5 mg/kg (recommended Phase II dose) on Day 1 of a 21-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate as Measured Per RECIST 1.1 Criteria</title>
          <description>Primary efficacy will be assessed based on radiological tumor evaluation by contrast-enhanced computed tomography (CT) or contrast-enhanced magnetic resonance imaging (MRI) of chest/abdomen/pelvis. Contrast enhanced RECIST 1.1 scan will be done at Prescreening. Said pre-screen scan will be the baseline measure. RECIST 1.1 Scans will be done every 6 weeks for the first 6 months after the start of treatment, or more frequently if clinically indicated, every 9 weeks until the end of year 2 and every 12 weeks thereafter until disease progression or end of study, whichever comes first.</description>
          <population>Of the 18 subjects originally enrolled, the analysis population includes the 14 subjects who completed the study. The original intention was to follow subjects for up to 3 years. However, all subjects died before the three year mark, so the study was concluded on Dec. 11.2019, after 2 years and 7 months.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>progressive disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>stable disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <description>Time to Progression (TTP) defined as time from study treatment to RECIST progression, or death (others going off study will be censored).</description>
        <time_frame>From start of treatment until disease progression or death (up to 3 years).</time_frame>
        <population>Of the 18 subjects originally enrolled, the analysis population includes the 14 subjects who completed the study. The original intention was to follow subjects for up to 3 years. However, all subjects died before the three year mark, so the study was concluded on Dec. 11.2019, after 2 years and 7 months.</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>Patients with advanced metastatic pancreatic cancer who have measurable disease&#xD;
anetumab ravtansine: Patients will receive anetumab ravtansine IV infusion at a dose of 6.5 mg/kg (recommended Phase II dose) on Day 1 of a 21-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <description>Time to Progression (TTP) defined as time from study treatment to RECIST progression, or death (others going off study will be censored).</description>
          <population>Of the 18 subjects originally enrolled, the analysis population includes the 14 subjects who completed the study. The original intention was to follow subjects for up to 3 years. However, all subjects died before the three year mark, so the study was concluded on Dec. 11.2019, after 2 years and 7 months.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.5" lower_limit="22" upper_limit="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Drug Toxicity</title>
        <description>Toxicity of Anetumab ravtansine assessed with National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. See adverse events for details. Participants who experienced any adverse events are included here.</description>
        <time_frame>From start of treatment until disease progression or death (up to 3 years).</time_frame>
        <population>Detailed results are included under adverse events. The original intention was to follow subjects for up to 3 years. However, all subjects died before the three year mark, so the study was concluded on Dec. 11.2019, after 2 years and 7 months.</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>Patients with advanced metastatic pancreatic cancer who have measurable disease&#xD;
anetumab ravtansine: Patients will receive anetumab ravtansine IV infusion at a dose of 6.5 mg/kg (recommended Phase II dose) on Day 1 of a 21-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Toxicity</title>
          <description>Toxicity of Anetumab ravtansine assessed with National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. See adverse events for details. Participants who experienced any adverse events are included here.</description>
          <population>Detailed results are included under adverse events. The original intention was to follow subjects for up to 3 years. However, all subjects died before the three year mark, so the study was concluded on Dec. 11.2019, after 2 years and 7 months.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other adverse events</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Three years.</time_frame>
      <desc>The original intention was to follow subjects for up to 3 years. However, all subjects died before the three year mark, so the study was concluded on Dec. 11.2019, after 2 years and 7 months.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Subjects</title>
          <description>Patients with advanced metastatic pancreatic cancer who have measurable disease&#xD;
anetumab ravtansine: Patients will receive anetumab ravtansine IV infusion at a dose of 6.5 mg/kg (recommended Phase II dose) on Day 1 of a 21-day cycle</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and Lymphatic System Disorders-other</sub_title>
                <description>Febrile Neutropenia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Obstruction Gastric</sub_title>
                <description>Obstruction Gastric</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <description>Abdominal Pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <description>Ascites</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Constipation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <description>Fever</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>General Disorders and administration-other specify Failure to Thrive</sub_title>
                <description>Failure to thrive</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>General Disorders and administration-other specify Death NOS</sub_title>
                <description>Death NOS</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>Sepsis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Infections and Infestations-other</sub_title>
                <description>Elevated White Blood Count</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Infections and Infestations-Other, specify-Rhinovirus</sub_title>
                <description>Rhino virus</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive Disturbance</sub_title>
                <description>Cognitive Disturbance</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <description>Stroke</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <description>Acute Kidney Injury</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Dyspnea</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <description>Hypoxia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Respiratory Failure (Pleural metastatic PD)</sub_title>
                <description>Respiratory Failure (Pleural metastatic PD)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Palmar Plantar Erythrodysesthes</sub_title>
                <description>Palmar Plantar Erythrodysesthes</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Hypotension</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Anemia</description>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Decreased Platelet Count</sub_title>
                <description>Decreased Platelet Count</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <description>Hyperlipidemia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>Thrombocytopenia</description>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <description>PTT Prolonged</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <description>Atrial fibrillation</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <description>Atrial flutter</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT corrected interval prolonged</sub_title>
                <description>Prolonged QTC</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <description>Left Ventricular Systolic Dysfunction</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <description>Sick Sinus Syndrome</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <description>Hearing impaired</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <description>Blurred Vison</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <description>Cataracts</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <description>Dry Eyes</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Eye disorders - Other, specify</sub_title>
                <description>Colorblindness</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <description>Right eye pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <description>Glaucoma</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Watering eyes</sub_title>
                <description>Watering Eyes</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <description>Abdominal distention</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Abdominal Pain</description>
                <counts group_id="E1" events="19" subjects_affected="12" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <description>Ascites</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Constipation</description>
                <counts group_id="E1" events="19" subjects_affected="11" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Diarrhea</description>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <description>Dry Mouth</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <description>Dyspepsia</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <description>Flatulence</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <description>GERD</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <description>Partial gastric outlet obstruction</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <description>Abdominal hernia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <description>Mouth sores</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <description>inguinal hernia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Malabsorption</sub_title>
                <description>Malabsorption</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Nausea</description>
                <counts group_id="E1" events="18" subjects_affected="9" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Occasional Epigastric Pain</sub_title>
                <description>Occasional Epigastric Pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <description>Sinus Tachycardia</description>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <description>small intestinal obstruction</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Vomiting</description>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <description>Weight Loss</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <description>Chills</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <description>Edema limbs</description>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Fatigue</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>fevers</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <description>Irritability</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <description>Non cardiac chest pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Pain (back/neck)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <description>Cold</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <description>Oral Thrush</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>URI/ Sinus Symptoms</sub_title>
                <description>URI/ Sinus Symptoms</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>Urinary tract infection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <description>Fall</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <description>Alanine Aminotransferase Elevated</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <description>Alkaline Phosphatase Increase</description>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <description>AST Increase</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <description>Elevated bilirubin</description>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cardiac troponin I increased</sub_title>
                <description>cardiac troponin i increased</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cholesterol high</sub_title>
                <description>High Cholesterol</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <description>Creatinine Increase</description>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>GGT increased</sub_title>
                <description>GGT increased</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypercholesterolemia</sub_title>
                <description>Hypercholesterolemia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Increased LDH</sub_title>
                <description>Increased LDH</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <description>Elevated INR</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Investigations- other, specify</sub_title>
                <description>Elevated LDH</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <description>Lipase</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <description>lymphocyte count decrease</description>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <description>platelet count decrease</description>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Serum amylase increased</sub_title>
                <description>Serum Amylase Increased</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <description>WBC Count Decrease</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>Anorexia</description>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>Dehydration</description>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diabetes</sub_title>
                <description>diabetes</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>GOUT</sub_title>
                <description>GOUT</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <description>hyperglycemia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <description>Hypokalemia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <description>Hyperuricemia</description>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <description>Hypoalbuminemia</description>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <description>Hypocalcemia</description>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <description>Hypokalemia</description>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>hypomagnesemia</sub_title>
                <description>Hypomagnesemia</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <description>Hyponatremia</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <description>Hypophosphatemia</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Metabolism and nutrition disorders - Other, specify</sub_title>
                <description>Decreased appetite</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>Arthralgias</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <description>Arthritis - knees / hands</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <description>Back pain</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <description>Generalized muscle weakness</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>myalgia</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Dizziness</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <description>Dysgeusia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Headache</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Investigations - Other, specify</sub_title>
                <description>Tremors</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <description>Neuropathy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <description>Bilateral Hands</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <description>Peripheral Sensory Neuropathy</description>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <description>Anxiety</description>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <description>Depression</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>Insomnia</description>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Psychiatric disorders - Other, specify</sub_title>
                <description>Mood Swings</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <description>Aacute kidney injury</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Bladder Cancer</sub_title>
                <description>Bladder Cancer</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <description>Hematuria</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <description>Proteinuria</description>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Renal and urinary disorders - Other, specify</sub_title>
                <description>Kidney stone</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <description>Urinary Frequency</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <description>urinary retention</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <description>Allergic Rhinitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>Dry Cough</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>Cough</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Dyspnea</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <description>Hiccups</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hoarseness</sub_title>
                <description>Hoarseness</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <description>Hypoxia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <description>Mucositis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <description>Pleural effusion</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sleep apnea</sub_title>
                <description>Sleep apnea</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <description>Sore Throat</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Basal Cell Carcinoma of Skin</sub_title>
                <description>Basal Cell Carcinoma of Skin</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Erythroderma</sub_title>
                <description>Facial Erythema</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <description>Pruritis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>Rash</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Hypertension</description>
                <counts group_id="E1" events="17" subjects_affected="7" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Orthostatic Hypotension</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <description>Orthostatic Hypotension</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Premature termination may occur if risk-benefit ratio is unacceptable due to: safety findings, results of parallel clinical studies and results of parallel animal studies AND if the study does not suggest a completion within a reasonable time frame.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Stacey Stein, MD</name_or_title>
      <organization>Yale University</organization>
      <phone>203 737-1600</phone>
      <email>stacey.stein@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

